Provided by Parkinson & Movement Disorder Alliance

This session covers evidence-based physical therapy interventions, including aerobic, resistance, balance, gait, and task-specific training, with an emphasis on improving functional outcomes, reducing motor disease severity, and enhancing quality of life. Participants will gain insights into best practices, external cueing strategies, rhythmic auditory stimulation, and integrated care approaches across all stages of Parkinson’s disease. Practical guidance on rehabilitation planning, including telerehabilitation and community-based exercise, is also included to equip healthcare professionals with actionable strategies for optimizing patient care.

Estimated time to complete activity: 75 minutes

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1 AMA PRA Category 1.25 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Discuss the APTA Physical Therapist Management of Parkinson Disease Clinical Practice Guideline
• Explain the specific action and best practice statements/recommendations of the APTA Physical Therapist Management of Parkinson Disease Clinical Practice Guideline 
• Evaluate the evidence-based physical therapy interventions for the management of freezing of gait 
• Analyze the evidence of incorporation of rhythmic auditory stimulation as an external cue for physical therapy and exercise interventions 
• Identify rehabilitative, compensatory, preventative, and health promotion approaches in physical therapy across the disease spectrum 
• Recognize the importance of intensity monitoring in physical therapy and exercise interventions for Parkinson Disease 
• Assess the evidence for plan of care clinical decision-making for a physical therapist in the management of Parkinson Disease 
• Design treatment plans that incorporate physical therapy for the management of Parkinson Disease

Faculty

Jared C. Braden PT, DPT, NCS
The Ohio State University Wexner Medical Center
OSU Physical Therapy Movement Disorder Fellowship Director
Board Certified Physical Therapy Neurologic Clinical Specialist

Jared Braden has been a physical therapist (PT) for 15 years with 11 years currently at The Ohio State University Wexner Center (OSUWMC). He has worked predominantly in the outpatient neurologic rehabilitation setting. He has been a board-certified physical therapy neurologic clinical specialist since 2016. He splits his time in clinical care, mentorship in the OSUWC geriatric PT residency program, and is the co-director of the OSUWMC/Bellarmine University and Norton Healthcare Neurologic PT Movement Disorder Fellowship. This joint fellowship is the first board accredited PT neurologic movement disorder fellowship in the country providing training to physical therapists in sub-specialization in the PT management of patients with movement disorders including but not limited to Parkinson disease (PD). He has additional certifications in PD-specific programming through Parkinson Wellness and Recovery (PWR!) and Lee Silverman Voice Therapy BIG program.

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Jared C. Braden PT, DPT, NCS
• Has no disclosures to report

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Leslie Cloud, MD
• Site investigator for research supported by Cereval Therapeutics, Bukwang Pharmaceutical, UCB Pharma, and Intracellular Therapies
• Speakers’ Bureau, consultant, and/or advisory board member for Kyowa Kirin and AbbVie

• Britt Stone, MD
• Consultant or advisory board for Boston Scientific

• Jason Rivera, MPH
• No disclosures to report

• Clarisse Goas, NP
• Principal or site investigator for research supported by Prilenia Therapeutics

• Anissa Mitchel, LCSW
• No disclosures to report

• Kelly Papesh, DNP
• Speakers’ Bureau, consultant, and/or advisory board member for Acadia, Amneal, and Supernus

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

This activity is supported by independent medical education grants from Acadia, Merz, AbbVie, Kyowa Kirin, and Ipsen.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org